Abivax’s (ABVX) “Buy” Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Abivax (NASDAQ:ABVX) in a report published on Wednesday,Benzinga reports. They currently have a $150.00 target price on the stock.

A number of other research firms also recently commented on ABVX. Piper Sandler restated an “overweight” rating and issued a $142.00 price objective on shares of Abivax in a report on Tuesday, December 16th. Wolfe Research upgraded Abivax to a “strong-buy” rating in a report on Thursday, November 6th. Citigroup reissued a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Finally, Morgan Stanley upped their price target on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $134.75.

Abivax Price Performance

NASDAQ ABVX opened at $121.28 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. The firm has a market capitalization of $9.59 billion, a price-to-earnings ratio of -29.01 and a beta of 0.79. The company has a 50 day simple moving average of $124.29 and a 200-day simple moving average of $105.84. Abivax has a 52-week low of $4.77 and a 52-week high of $148.83.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The business had revenue of ($4.92) million for the quarter. Equities research analysts predict that Abivax will post -2.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abivax

A number of hedge funds have recently modified their holdings of ABVX. EverSource Wealth Advisors LLC boosted its stake in Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after buying an additional 369 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Abivax by 661.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after acquiring an additional 344 shares in the last quarter. First Horizon Corp bought a new position in shares of Abivax during the third quarter valued at $36,000. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Abivax in the 4th quarter valued at $61,000. Finally, WPG Advisers LLC grew its holdings in shares of Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after purchasing an additional 253 shares during the last quarter. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.